PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Cannabis Investing PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
Cannabis Investing PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program
PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
Cannabis Investing PreveCeutical Applies its Proprietary Extraction Protocol for Medical Cannabinoids to Two Additional Cannabis Strains
Pharmaceutical Investing PreveCeutical Holds Intensive Workshop to Advance Dual Gene Therapy Research Program for Type 2 Diabetes and Obesity
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
